
### **Events and Presentations**

Browse the calendar to view Investor related events and announcements. Webcasts and presentations that have been archived are available by viewing historical event details.



friday, November 3, 2023 - Sunday, November 5, 2023

# **Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting**

**Title:** Phase 1/2 Study of the Bispecific 4-1BB and PD-L1 Antibody INBRX-105 Alone and in Combination With Pembrolizumab in Select Solid Tumors

**Lead Author:** Jong Chul Park, MD

Abstract: 742

Location: San Diego Convention Center, San Diego, CA - Hall A

Trial-in-progress poster presentation on Saturday, November  $4^{th}$ , 2023 from 9 AM – 8:30 PM Pacific Standard Time

Title: Phase 1/2 Study of the Hexavalent OX40 Agonist INBRX-106 Alone and in Combination With

Pembrolizumab in Select Solid Tumors **Lead Author:** Rachel E. Sanborn, MD

Abstract: 748

Location: San Diego Convention Center in San Diego, CA - Hall A

Trial-in-progress poster presentation on Saturday, November  $4^{th}$ , 2023 from 9 AM – 8:30 PM Pacific Standard Time

- Download INBRX-105 Presentation (2 MB)
- Download INBRX-106 Presentation (1.6 MB)
- Download Providence INBRX-106 Mouse Study (851 KB)

## **Connective Tissue Oncology Society (CTOS) 2023 Annual Meeting**

Title: The Tetravalent Death Receptor 5 Agonist INBRX-109 Combined With Chemotherapy in Ewing Sarcoma:

Preliminary Data From A Phase 1 Study **Lead Author:** Rashmi Chugh, MD

Location: The Liffey Convention Centre in Dublin, Ireland

Poster presentation on Thursday, November 2<sup>nd</sup>, 2023 from 5:30 PM - 6:30 PM Irish Standard Time

## **Download Presentation**

(1.4 MB)

#### October 2023

**O** 11:30am EDT

#### Poster Presentation at AAPS PharmSci360 Conference

Title: PABE: A Novel Enhanced Drug Tolerant assay format to detect Anti-Drug Antibodies in the presence of

high concentrations of rhAAT-Fc

**Poster:** M1130-06-39 **Abstract:** 1587254

Lead Author: Varun Ramani

Monday, October 23, 2023 at 11:30 AM EST

Presented at the AAPS PharmSci 360 conference at the Orange County Convention Center, Orlando, Florida

**Download Poster Presentation** (962 KB)

#### September 2023

Monday, September 11, 2023

# Validation of assays measuring functional alpha-1 antitrypsin (AAT) in patients with AAT deficiency (AATD)

Poster ID: 3052 Abstract: 42388

Author: Carson Veldstra

Monday, September 11, 2023; 00:30-02:00 EDT

Presented at the European Respiratory Society (ERS) International Congress 2023

#### **Download ePoster**

(1.3 MB)

#### **June 2023**

Listen to the Webcast

### Jefferies Global Healthcare Conference

Mark Lappe, CEO fireside chat on June 7th, 2023 at 10am ET

#### May 2023

## **American Thoracic Society (ATS) Annual International Conference**

Presentation Title: Recombinant Human Alpha-1 Antitrypsin (AAT) Protein INBRX-101 Demonstrates Potential

to Achieve Lung Penetration and Normal Functional Serum AAT Levels in Patients With AAT Deficiency

Lead Author: B.T. Kuhn

Session Title: Mini Symposium. C15. EMERGING COPD DIAGNOSTICS AND TREATMENTS

**Session Date/Time:** May 23<sup>rd</sup>, 2023; 9:00 AM - 11:00 AM Eastern Time **Presentation Date/Time:** May 23<sup>rd</sup>, 2023; 9:24 AM - 9:36 AM Eastern Time **Location:** Walter E. Washington Convention Center, Ballroom B (Level 3)

Exhibit Booth hours and location: May 21st- May 23rd, 2023 between 10:30 a.m. - 3:30 p.m. Eastern Time;

Booth CT9 in Hall D.

**Download ePoster** (647 KB)

Download Presentation (2.1 MB)

**1:50pm EDT** 

## 19th Annual PEGS Boston Conference & Expo

**Download Presentation** (4.3 MB)

#### **November 2022**

∰ Wednesday, November 30, 2022② 8:45am PST

Listen to the Webcast

The Evercore ISI 5th Annual HealthCONx Conference

# Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting to be held November 16th - 19th, 2022 in Vancouver, BC, Canada

Title: Updated Efficacy and Safety of the Tetravalent Death Receptor 5 Agonist INBRX-109 in Patients with Chondrosarcoma: Data from the Phase 1 Expansion

Cohorts

Lead Author: Sant P. Chawla, MD Abstract: 2206531, Poster (P 043)

Date & Time: November 19, 2022, 4:36 p.m. - 4:44

p.m. EST

Title: INBRX-109 in Ewing Sarcoma: Preclinical Rationale for Initiation of a Phase 1 Chemotherapy

Combination Expansion Cohort

Lead Author: Nehal J. Lakhani, MD, PhD Abstract: 2206541, Poster (P 324)

Date & Time: November 17th, 2022, 5:00 p.m. - 7:00

p.m. EST

Title: A Randomized, Placebo-Controlled Phase 2 Trial of INBRX-109 in Unresectable or Metastatic

Conventional Chondrosarcoma

Lead Author: Robin Lewis L. Jones, MD Abstract: 2206600, Poster (P 322)

Date & Time: November 17th, 2022, 5:00 p.m. - 7:00

p.m. EST

- CTOS 2022- INBRX-109 Chondrosarcoma expansion cohorts (4.8 MB)
- CTOS 2022- INBRX-109 Rationale for Ewing in combination with Chemo (4.8 MB)
- CTOS 2022- INBRX-109 Phase 2 Chondrosarcoma TiP (6.6 MB)

Tuesday, November 8, 2022 - Saturday, November 12, 2022

# Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting to be held November 8th - 12th, 2022 in Boston, Massachusetts

Title: Development of a Molecular Targeted Cytokine that Specifically Expands Vg9Vd2 T-cells and Potentiates Anti-tumor Activity Lead Author: Bryan Becklund, PhD

Abstract/Poster: 3513 / 15

Abstract: 1077

Date & Time: Thursday, November 10th, 2022, 9:00 a.m. - 9:00 p.m. EST and Friday, November 11th, 2022,

9:00 a.m. - 8:30 p.m. EST



Load More Events



https://inhibrx.investorroom.com/events-and-presentations